Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
18 October 2022 - 11:30PM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a biopharmaceutical company using advanced cell
engineering technology to develop transformational new medicines,
today announced that Matt Angel, Ph.D., Interim Chief Executive
Officer of Eterna, will present at the iPSC-Derived Immunotherapies
Congress, taking place October 18-19, 2022 in Boston.
Details of Presentation
Title: Avoiding Vector Integration Using mRNA
Vectorization of Reprogramming and Gene Editing
ProteinsPresenter: Matt Angel, Ph.D., Interim
Chief Executive Officer of EternaDate: October 18,
2022Time: 3:10 p.m. ETLocation:
Hilton Boston Back Bay Hotel, 40 Dalton St., Boston, Massachusetts
02115
About Eterna TherapeuticsEterna is focused on
developing advanced therapies using state-of-the-art mRNA cell
engineering technology. Its mission is to realize the potential of
cell engineering to provide patients with transformational new
medicines. The Company has in-licensed a portfolio of over 100
patents covering key cell engineering technologies, including what
it believes are the most widely used methods for therapeutic gene
editing currently in clinical development. Eterna has multiple
next-generation cell and gene-editing therapies in preclinical
development for various indications. For more information, please
visit www.eternatx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Eterna’s business model into a platform company
focused on cellular, gene editing and cytokine programs; (ii)
Eterna’s ability to successfully, cost-effectively and efficiently
develop its technology and products; (iii) Eterna’s ability to
successfully commence clinical trials of any products on a timely
basis or at all; (iv) Eterna’s ability to successfully fund and
manage the growth of its development activities; (v) Eterna ’s
ability to obtain regulatory approvals of its products for
commercialization; and (vi) uncertainties related to the impact of
the COVID-19 pandemic on the business and financial condition of
Eterna, including on the timing and cost of its clinical trials.
You should not rely upon forward-looking statements as predictions
of future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2021, as amended, as well as under similar
headings in Eterna’s subsequently filed Quarterly Reports on Form
10-Q and Current Reports on Form 8-K.
Investor Relations
Contact:investors@eternatx.com
Media Contact:Jon YuICR
Westwicke475-395-5375EternaPR@westwicke.com
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Apr 2023 to Apr 2024